Clinical Trial Update: Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) [Phase 2]

View source ↗

Summary

Phase 2 study of danicopan in Paroxysmal Nocturnal Hemoglobinuria completed with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• Danicopan (danicopan)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 2 | Status: COMPLETED | Results posted: 2021-06-02